Algeta to host Capital Markets Days
(Thomson Reuters ONE) -
Not intended for US media
Oslo, Norway, 18 November 2013 - Algeta ASA (OSE: ALGETA), a company focused on
the development of novel targeted cancer therapeutics, will host Capital Markets
Days this week in Oslo, London and New York.
Presentations by Algeta's Executive Management and invited guest speakers will
cover topics including alpha-pharmaceutical production, a commercial update and
the current life-cycle management clinical trial plan for Xofigo(®) (radium Ra
223 dichloride) as well as Algeta's pipeline of Targeted Thorium Conjugates.
Event summaries and guest speaker details are provided below.
Oslo, 18 November 10:00am-2:00pm (CET)
KS-Agenda Møtesenter, Haakon VII's gate 9
* Dr Dag Clement Johannessen, Consultant Oncologist, Department of Oncology,
University Hospital of Oslo, Norway
* Dr Sten Nilsson, Professor of Oncology, Karolinska Institutet and University
Hospital, Stockholm, Sweden
London, 19 November 10:00am-2:00pm (GMT)
Holborn Bars 2(nd) Floor, 138-142 Holborn
* Dr E. David Crawford, Professor of Surgery (Urology) & Radiation Oncology,
Head Urologic Oncology, University of Colorado, Denver, USA
* Dr Sten Nilsson, Professor of Oncology, Karolinska Institutet and University
Hospital, Stockholm, Sweden
New York, 21 November 12.30pm-4:30pm (EDT)
Parker Meridien, 118 West 57(th) Street
* Dr Dan George, Director, GU Oncology, Duke Cancer Institute, Duke University
Medical Center, Durham, North Carolina, USA
* Dr Neal D. Shore, Director, CPI, Carolina Urologic Research Center, Atlantic
Urology Clinics, Myrtle Beach, South Carolina, USA
The event in New York will be webcast via www.algeta.com, where presentations
will also be made available.
About Xofigo(®) (Radium Ra 223 Dichloride)
Xofigo is approved in Europe for the treatment of adults with castration-
resistant prostate cancer, symptomatic bone metastases and no known visceral
metastases. Xofigo is an alpha particle-emitting pharmaceutical. Its active
moiety mimics calcium and selectively targets bone, specifically areas of bone
metastases, by forming complexes with the bone mineral hydroxyapatite. The high
linear energy transfer of alpha emitters (80 keV/micrometer) leads to a high
frequency of double-strand DNA breaks in adjacent tumour cells, resulting in a
potent cytotoxic effect. Additional effects on the tumour microenvironment
including osteoblasts and osteoclasts also contribute to the in vivo efficacy.
The alpha particle range from radium-223 is less than 100 micrometers (less than
10 cell diameters) which minimises damage to the surrounding normal tissue.
Xofigo is also approved in the US for the treatment of castration-resistant
prostate cancer, symptomatic bone metastases and no known visceral disease.
In September 2009, Algeta signed an agreement with Bayer for the development and
commercialization of radium-223. Under the terms of the agreement, Bayer will
develop, apply for health authority approvals worldwide and commercialize Xofigo
globally. Algeta is eligible for royalties and milestones based on Bayer's sales
of Xofigo outside the US, and Algeta US, LLC is co-promoting Xofigo with Bayer
in the US.
Xofigo(®) is a registered trademark of Bayer AG
###
For further information, please contact:
Mike Booth +1 646 410 1884
Communications & Corporate Affairs ir(at)algeta.com
Media enquiries:
Mark Swallow +44 207 638 9571
Citigate Dewe Rogerson mark.swallow(at)citigatedr.co.uk
Knut Ekern +47 22 04 82 00
Gambit Hill & Knowlton knut.ekern(at)hkstrategies.com
Investor enquiries:
Tricia Truehart +1 646 378 2953
The Trout Group ttruehart(at)troutgroup.com
About Algeta
Algeta is a company focused on developing, manufacturing and marketing novel
targeted therapies for patients with cancer. The Company is headquartered in
Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA
performing commercial marketing operations in the US. Algeta is listed on the
Oslo Stock Exchange (Ticker: ALGETA). For more information please visit
www.algeta.com.
This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
Press release:
http://hugin.info/134655/R/1743765/586642.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Algeta ASA via Thomson Reuters ONE
[HUG#1743765]
Unternehmensinformation / Kurzprofil:
Datum: 18.11.2013 - 07:00 Uhr
Sprache: Deutsch
News-ID 317395
Anzahl Zeichen: 5747
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 224 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Algeta to host Capital Markets Days"
steht unter der journalistisch-redaktionellen Verantwortung von
Algeta ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
